Expands Pipeline with Anti-IgE License, Raises $30M in Private Placement
Summary
Cue Biopharma has licensed an anti-IgE asset from Ascendant Health Sciences, involving a $15 million upfront payment and potential milestones up to $676.5 million. Concurrently, the company secured approximately $30 million through a private placement of pre-funded and five-year warrants. This capital infusion is critical, directly addressing the company's previously disclosed substantial doubt about its ability to continue as a going concern and its limited cash runway into Q1 2027, as highlighted in its recent 10-K filing. The licensing deal also expands Cue Biopharma's pipeline with a late-stage asset, providing a new potential growth driver. Investors will closely watch the progress of the newly licensed program and the effective deployment of the raised capital to stabilize operations and advance the pipeline.
At the time of this announcement, CUE was trading at $27.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88M. The 52-week trading range was $4.97 to $33.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.